Today: 7 February 2026
Subscribe
Browse Category

Clinical Trials News 22 December 2025 - 31 December 2025

Ultragenyx stock today: RARE steadies premarket after setrusumab Phase 3 miss, FDA gene-therapy filing in focus

Ultragenyx stock today: RARE steadies premarket after setrusumab Phase 3 miss, FDA gene-therapy filing in focus

NEW YORK, December 31, 2025, 09:15 ET — Premarket Ultragenyx Pharmaceutical (RARE.O) shares edged down 0.2% to $22.74 in premarket trading on Wednesday, after finishing Tuesday up 15.5% at $22.78. The stock’s 52-week range is $18.41 to $46.50. StockAnalysis The rare-disease drugmaker is trying to find its footing after a sharp two-day repricing driven by a late-stage clinical setback that hit one of its higher-profile pipeline programs. The next question for investors is whether Ultragenyx can quickly shift attention from a failed bone-disease readout to nearer-term regulatory milestones in gene therapy, while cutting costs to protect cash. Ultragenyx said on
31 December 2025
····
Amgen stock dips as Lumakras combo trial ends; MariTide data now the next watch

Amgen stock dips as Lumakras combo trial ends; MariTide data now the next watch

NEW YORK, December 30, 2025, 2:56 PM ET — Regular session Amgen Inc. shares were down 0.4% at $328.32 at 2:56 p.m. ET on Tuesday, after trading between $325.90 and $330.18. The modest move matters because investors are grading Amgen’s pipeline for new growth while several mature products face price pressure and biosimilar competition. Oncology and obesity remain two key swing factors for the stock heading into 2026. Biotech stocks lagged, with the iShares Nasdaq Biotechnology ETF down about 1.1%, while the healthcare sector ETF was roughly flat and the S&P 500 ETF hovered near unchanged. Verastem Oncology said it
30 December 2025
····
Zenas BioPharma stock slides 5% today as biotech shares sag; Phase 3 INDIGO data in focus

Zenas BioPharma stock slides 5% today as biotech shares sag; Phase 3 INDIGO data in focus

NEW YORK, December 30, 2025, 02:05 PM ET — Regular session Zenas BioPharma Inc shares fell $2.02, or 5.2%, to $37.03 in afternoon trading on Tuesday, after ending the prior session at $39.05. The stock ranged from $36.94 to $40.50, with about 123,000 shares traded. The drop came as biotech stocks eased in thin year-end trading, with the Nasdaq Biotechnology Index down about 1%. That matters now because smaller, cash-burning drug developers often move with risk appetite as much as on headlines. indexes.nasdaqomx.com Wall Street’s main indexes were largely muted as investors waited for minutes from the Federal Reserve’s December
30 December 2025
·····
Zenas BioPharma (ZBIO) stock steadies in premarket after 8% slide as INDIGO trial timing stays in focus

Zenas BioPharma (ZBIO) stock steadies in premarket after 8% slide as INDIGO trial timing stays in focus

NEW YORK, December 30, 2025, 09:17 ET — Premarket Zenas BioPharma, Inc. shares were flat in premarket trading on Tuesday, with the stock last indicated at $39.05 as of 9:00 a.m. ET. The biotech closed down 8.1% on Monday. Public+1 The pause comes at a sensitive point on the calendar for investors: the company has told investors to expect a late-2025 update from a pivotal trial, a headline that can reset valuations quickly in clinical-stage biotech. In a Nov. 12 press release, founder and Chief Executive Officer Lonnie Moulder said the company expected to deliver “topline results” — the first
30 December 2025
···
SELLAS Life Sciences (SLS) stock jumps on Phase 3 AML trial timing update — what investors watch next

SELLAS Life Sciences (SLS) stock jumps on Phase 3 AML trial timing update — what investors watch next

NEW YORK, December 30, 2025, 01:49 ET — Market closed SELLAS Life Sciences Group Inc (SLS) shares jumped 16.7% on Monday to close at $3.35 after the company updated investors on the timing of a late-stage acute myeloid leukemia (AML) trial. The stock traded between $2.60 and $3.44 and logged about 22.4 million shares, according to StockAnalysis data. StockAnalysis The update matters because REGAL is the company’s main near-term catalyst, and the market is trying to pin down when the final dataset will be ready. In biotech, a change in timing can move shares even when there is no new
30 December 2025
····
Mereo BioPharma stock crashes 88% after Phase 3 setrusumab miss sinks brittle-bone hopes

Mereo BioPharma stock crashes 88% after Phase 3 setrusumab miss sinks brittle-bone hopes

NEW YORK, December 29, 2025, 23:16 ET — Market closed Mereo BioPharma Group plc shares closed down 87.65% at $0.29 on Monday after the company disclosed late-stage data that failed to hit a key fracture-rate endpoint for setrusumab, its lead rare-disease program. The stock traded between $0.20 and $0.30, with about 241 million shares changing hands, according to the company’s share data. Mereo BioPharma The miss lands at a delicate moment for the London-based biotech, which has leaned on setrusumab as its most visible late-stage value driver. Investors are now weighing how quickly the company can rein in spending and
30 December 2025
····
Ultragenyx stock sinks 42% after Phase 3 setrusumab miss; what RARE investors watch nextNEW YORK, December 29, 2025, 23:21 ET — Market closed

Ultragenyx stock sinks 42% after Phase 3 setrusumab miss; what RARE investors watch nextNEW YORK, December 29, 2025, 23:21 ET — Market closed

Ultragenyx Pharmaceutical Inc shares slid on Monday after the company said two late-stage studies of setrusumab for osteogenesis imperfecta missed their primary fracture-reduction goal, prompting plans for significant expense reductions. “We are surprised and disappointed by these results,” Chief Executive Emil Kakkis said. Shares last traded down 42.3% at $19.72 after the close, versus a prior close of $34.19, after swinging between $34.50 and $17.76 on volume of about 21.7 million shares. Stock Titan The miss dents a key growth bet for Ultragenyx in a rare genetic bone disorder often called brittle-bone disease. Late-stage trial outcomes can quickly reshape expectations
30 December 2025
··
Johnson & Johnson stock (JNJ) holds near $208 as J&J halts eczema trial; what investors should watch before Monday’s open

Johnson & Johnson stock (JNJ) holds near $208 as J&J halts eczema trial; what investors should watch before Monday’s open

NEW YORK, Dec. 28, 2025, 3:26 p.m. ET — Market closed Johnson & Johnson stock (NYSE: JNJ) heads into the final trading week of 2025 with U.S. markets shut for the weekend and investors sorting through a fresh pipeline headline that surfaced late Friday. With the New York Stock Exchange closed today and the next regular session set for Monday, Dec. 29, attention is shifting to what could move JNJ when trading resumes—including biotech read-throughs, litigation headlines, and year-end macro catalysts in a holiday-shortened week. New York Stock Exchange+2Investopedia+2 As of the latest available market data, JNJ last traded around
28 December 2025
···
Johnson & Johnson Stock (JNJ) Update: Shares Hold Near $208 as Markets Close for the Weekend; Eczema Trial Halt, Pipeline Wins, and 2026 Outlook in Focus

Johnson & Johnson Stock (JNJ) Update: Shares Hold Near $208 as Markets Close for the Weekend; Eczema Trial Halt, Pipeline Wins, and 2026 Outlook in Focus

NEW YORK, Dec. 27, 2025, 3:33 PM ET — Market closed Johnson & Johnson (NYSE: JNJ) stock is heading into the final trading days of 2025 with U.S. markets closed for the weekend and year-end liquidity typically thinning across Wall Street. JNJ last closed at $207.63 on Friday, down 0.07% on the day, and was last indicated around $207.86 in after-hours trading, according to widely followed market data. Investing.com+1 For investors, the key question before Monday’s open is whether the latest company-specific headline—a discontinued mid-stage eczema (atopic dermatitis) trial—changes the near-term narrative for a stock that has been trading in
27 December 2025
····
Abivax (ABVX) Stock in Focus: Eli Lilly Takeover Chatter, Obefazimod Phase 3 Momentum, and What to Watch Before the Next U.S. Session

Abivax (ABVX) Stock in Focus: Eli Lilly Takeover Chatter, Obefazimod Phase 3 Momentum, and What to Watch Before the Next U.S. Session

NEW YORK — Friday, December 26, 2025 (9:13 a.m. ET): U.S. stocks are heading into a thin, post‑Christmas trading day, with Wall Street set for a relatively muted open as investors digest a strong 2025 tape and look ahead to 2026 rate and earnings narratives. Reuters In that kind of tape, headline-driven biotech names can swing harder than usual—and ABIVAX Société Anonyme (NASDAQ: ABVX) has been exactly that kind of stock in December: a mix of clinical-trial enthusiasm, index-related positioning, and renewed takeover speculation. As of the latest available quote this morning, ABVX was trading around $145.31 in the premarket,
26 December 2025
·····
SELLAS Life Sciences (SLS) Stock Update: ASH 2025 Data, REGAL Trial Countdown, Analyst Targets, and Key Risks (Dec. 23, 2025)

SELLAS Life Sciences (SLS) Stock Update: ASH 2025 Data, REGAL Trial Countdown, Analyst Targets, and Key Risks (Dec. 23, 2025)

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) is closing out 2025 on a familiar biotech cocktail: fresh clinical data, a major late-stage catalyst approaching, and market activity that suggests traders are positioning for volatility. As of 12:22 UTC on Tuesday, Dec. 23, 2025, SLS stock traded around $2.64, according to market data. In the prior session, the stock closed around $2.64 after moving sharply higher on heavy volume (roughly 8.9 million shares)—a notable burst for a small-cap biotech. Investing.com So what’s behind the renewed attention? In short: SELLAS just presented updated Phase 2 AML data for SLS009 at ASH 2025,
23 December 2025
···
Zenas BioPharma (ZBIO) Stock Hits a Record High on Dec. 22, 2025 as INDIGO Phase 3 Catalyst Nears — Latest News, Analyst Forecasts, and What’s Next

Zenas BioPharma (ZBIO) Stock Hits a Record High on Dec. 22, 2025 as INDIGO Phase 3 Catalyst Nears — Latest News, Analyst Forecasts, and What’s Next

Zenas BioPharma, Inc. (NASDAQ: ZBIO) is having one of those classic biotech days where the market starts acting like it can see the future. On Monday, December 22, 2025, ZBIO surged roughly 14% and traded around $41.23 by early afternoon Eastern time—after touching a fresh all-time high near $41.67, according to multiple market data reports. MarketBeat+1 The timing isn’t subtle: Zenas is approaching a pivotal clinical-data moment for its lead asset obexelimab, and Wall Street research desks are increasingly framing the stock as a near-term catalyst setup—high potential reward, high potential whiplash. Below is a full roundup of the news,
22 December 2025
····
1 2 3 4 5 6 … 9

Stock Market Today

Go toTop